Real‐world outcome with abiraterone acetate plus prednisone in Asian men with metastatic castrate‐resistant prostate cancer: The Singapore experience
| Autor: | Ker Yun Loh, Melvin L.K. Chua, Quan Sing Ng, Yian Ching Fong, Heng Chi Lim, Lui Shiong Lee, Ravindran Kanesvaran, T. Rajasekaran, Johan Chan, Alvin Wong, Siew Wei Wong, Marcus Way Lunn Chow, Chee Keong Toh, Shi Yin Yap |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Adult
Male Subset Analysis medicine.medical_specialty Abiraterone Acetate Anti-Inflammatory Agents 03 medical and health sciences chemistry.chemical_compound Prostate cancer 0302 clinical medicine Prednisone Internal medicine medicine Humans 030212 general & internal medicine Adverse effect Aged Retrospective Studies Aged 80 and over Singapore business.industry Incidence (epidemiology) Abiraterone acetate General Medicine Middle Aged Prognosis medicine.disease Survival Rate Prostatic Neoplasms Castration-Resistant Oncology chemistry 030220 oncology & carcinogenesis Prednisolone Drug Therapy Combination business medicine.drug Cohort study |
| Zdroj: | Asia-Pacific Journal of Clinical Oncology. 16:75-79 |
| ISSN: | 1743-7563 1743-7555 |
| DOI: | 10.1111/ajco.13241 |
| Popis: | INTRODUCTION Several small studies have reviewed the efficacy of abiraterone acetate plus prednisolone (AAP) in clinical practice outside a trial setting. We report the largest cohort study of clinical outcomes in metastatic castrate-resistant prostate cancer (mCRPC) patients treated with AAP in a multicenter multiracial clinical setting. METHODS A retrospective analysis on mCRPC patients treated at four tertiary hospitals in Singapore from 2012 to 2017 was conducted. Disease characteristics, treatment outcomes, and adverse events were retrieved from electronic medical records. Primary clinical end-point was overall survival (OS). A subset analysis of patients with various variables and OS curves were generated using the Kaplan-Meier method and compared using the log-rank test. RESULTS Out of 200 patients with mCRPC treated with AAP, 163 (81.5%) patients were chemo-naive (CN) and 37 (18.5%) patients were postchemotherapy (PC), with the median age of 68 (34-87) and 65 (52-80) years, respectively. Median OS was 20.0 (95% CI, 18.3-22.9) and 10.5 months (95% CI, 1.1-40.5) for CN and PC cohorts, respectively. A subset analysis of 108 patients showed a significantly longer OS in patients who had prior ADT for more than 12 months in CN patients (P < 0.001). Incidences of G3/G4 events were around 6.6%; most common side effect being hypertension with an incidence of 2.4%. CONCLUSIONS Treatment of CN and PC patients with AAP was associated with a comparable OS and progression-free survival to the reported series. Patients who were responsive to prior ADT of 12 months or more were associated with an improved OS. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|